What Does It Mean By FDA Accelerated Approval Of Cancer Drugs?

Written and edited by Abel B. Daartey, PharmD

When you or someone you love is facing cancer, waiting is not an abstract problem. It is the time between appointments, the next scan, and the worry that another treatment might stop working.

So, a headline announcing a newly approved cancer drug can bring real hope. But “FDA approved” does not always tell us how much is already known about that treatment. Sometimes, access comes while an important part of the evidence is still being collected.

That is the idea behind the FDA’s accelerated approval pathway: allow earlier access to certain medicines for serious conditions with an unmet medical need, while requiring further work to verify their clinical benefit. [1]

3 Key Takeaways

Accelerated approval can make a cancer treatment available before its expected clinical benefit has been fully verified.
Tumor shrinkage is useful evidence, but it does not automatically mean people will live longer or feel better.
Confirmatory studies matter. They can support traditional approval, but disappointing findings can also lead to withdrawal of a particular use.

Why Earlier Access Matters

The pathway began in 1992 in response to the HIV/AIDS crisis. Cancer and blood cancer treatments now account for most accelerated approvals. The same problem runs through both settings: patients may need an option before researchers can collect years of follow-up data. [2]

Accelerated approval can rely on a surrogate endpoint, a measurable change considered reasonably likely to predict clinical benefit. In cancer, this often means the proportion of patients whose tumors shrink, interpreted alongside how long those responses last. The FDA still evaluates safety and effectiveness; the uncertainty concerns whether the measured effect will translate into the expected clinical benefit. [1] [2]

Beyond Tumor Shrinkage

Imagine a study in which a new drug shrinks tumors in some participants. That finding shows activity against the cancer. It does not, by itself, establish that patients live longer, have fewer symptoms, or experience a better quality of life. Side effects and the duration of the response also matter. [3]

There is another detail that often gets lost in drug headlines. Traditional approval does not always require an overall survival benefit. Depending on the cancer, the size of the effect, and the balance of benefits and harms, other outcomes can support approval. One is progression-free survival, the time before cancer worsens or a patient dies. Confirmatory trials can also use outcomes other than survival or quality of life. [3]

So, when reading about a new medicine, I would look beyond the word “approved” and ask what the study actually measured.

Successes and Setbacks

Imatinib (Gleevec) shows why earlier access can matter. It first received accelerated approval for certain patients with chronic myeloid leukemia in 2001. Imatinib and the targeted treatments that followed helped make long-term disease control possible for many people with this leukemia. That is a major achievement, although it should not be taken as a guarantee for every drug using the pathway. [4]

Bevacizumab (Avastin) offers a different lesson. Its approval with paclitaxel for previously untreated metastatic HER2-negative breast cancer was withdrawn in 2011. Follow-up trials did not confirm the magnitude of benefit initially seen, and the modest benefit did not justify the serious adverse effects. This decision concerned that specific breast cancer use, rather than every use of bevacizumab. [5] [6]

What the Data Show

An FDA review covering 93 cancer indications granted accelerated approval from 1992 through May 2017 found that 51, or 55%, had verified benefit by the review’s cutoff. Among those, the median time from accelerated approval was 3.4 years. These are historical findings, not a current success rate. [7]

A 2024 study asked a more patient centered question. Among 46 cancer indications approved through the pathway in 2013–2017, with at least five years of follow-up, 29 had converted to regular approval. However, only 20 of the 46 had demonstrated improved overall survival or quality of life in confirmatory trials. The researchers assessed evidence through 2023. [8]

That does not establish that every remaining treatment was ineffective. Some approvals rested on other outcomes, and some trials were still pending. It does show why regulatory conversion and demonstrated survival or quality of life benefit should be reported separately. [8]

Finishing the Research

Confirmatory evidence may come from a separate study or from longer follow-up within the same trial. In its March 2023 draft guidance, the FDA expressed a preference for randomized trials, which assign participants to treatment groups and help compare benefits and harms. It also acknowledged circumstances where a single-arm study may be appropriate. [10]

Legislation enacted in December 2022 gave the FDA explicit authority to require a confirmatory study to be underway before approval, or within a specified period afterward, as appropriate. It also provided additional tools for timely study completion and expedited withdrawal. [9]

The FDA’s January 2025 draft guidance proposes considering enrollment, a credible completion date, and sufficient progress toward finishing the trial when deciding whether a study is “underway.” As of October 19, 2026, the FDA still lists this document as draft guidance, not for implementation. The proposed recommendations should be distinguished from the agency’s existing legal authority. [9]

Ask Your Care Team

The FDA’s Project Confirm tracks ongoing, verified, and withdrawn cancer accelerated approvals. The status relates to a specific indication, meaning a particular disease and treatment setting. A drug’s prescribing information also identifies a use granted accelerated approval. [2]

What makes this treatment a suitable option for my cancer and previous treatments?
Did the studies show tumor shrinkage, delayed progression, longer survival, or better quality of life?
Has the benefit been verified for this particular use, and what is the confirmatory study testing?
How do the likely benefits and side effects compare with my alternatives, including clinical trials?

Hope and Evidence

As a pharmacist and cancer researcher, I see the appeal of getting a promising treatment to patients sooner. I also think patients deserve a clear account of what remains uncertain. That is my interpretation of the evidence: earlier access has value, and the responsibility to finish the research comes with it.

A useful drug headline should leave room for both hope and questions. Which part of the approval process would you like me to explain next?

References

Evidence checked October 19, 2026. This article is for education and does not replace advice from your oncology team. Do not stop or change a cancer treatment without discussing it with your treating clinician.

Image generated with OpenAI.